Search research articles
Contact Us
Filters
Showing results (41-50 of 313) with videos related to
Page
of 32
Sort By:
Lancet (London, England)
|
May 27, 2008
Intensive insulin therapy in newly diagnosed type 2 diabetes
Ravi Retnakaran, Daniel J Drucker
Regulatory Peptides
|
March 23, 2005
GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice
Tanya Hansotia, Daniel J Drucker
Endocrinology
|
October 18, 2007
Glucagon-like peptide 1 and type 1 diabetes: NOD ready for prime time?
Irene Hadjiyanni, Daniel J Drucker
Endocrine Reviews
|
October 13, 2016
Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance
Gemma Pujadas, Daniel J Drucker
Molecular Endocrinology (Baltimore, Md.)
|
September 28, 2002
Pax-2 activates the proglucagon gene promoter but is not essential for proglucagon gene expression or development of proglucagon-producing cell lineages in the murine pancreas or intestine
Grace Flock, Daniel J Drucker
American Journal of Physiology. Endocrinology and Metabolism
|
January 1, 2009
Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes
Safina Ali, Daniel J Drucker
Annual Review of Medicine
|
January 18, 2006
Therapeutic approaches to preserve islet mass in type 2 diabetes
Laurie L Baggio, Daniel J Drucker
The Journal of Nutrition
|
November 11, 2003
Dual regulation of cell proliferation and survival via activation of glucagon-like peptide-2 receptor signaling
Jennifer L Estall, Daniel J Drucker
Endocrinology
|
November 30, 2019
Proglucagon-Derived Peptides, Glucose-Dependent Insulinotropic Polypeptide, and Dipeptidyl Peptidase-4-Mechanisms of Action in Adipose Tissue
Jacqueline L Beaudry, Daniel J Drucker
Annual Review of Nutrition
|
April 11, 2006
Glucagon-like Peptide-2
Jennifer L Estall, Daniel J Drucker
Page
of 32
Search research articles
Search
Showing results (41-50 of 313) with videos related to
Sort By:
Page
of 32
Lancet (London, England)
|
May 27, 2008
Intensive insulin therapy in newly diagnosed type 2 diabetes
Ravi Retnakaran, Daniel J Drucker
Regulatory Peptides
|
March 23, 2005
GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice
Tanya Hansotia, Daniel J Drucker
Endocrinology
|
October 18, 2007
Glucagon-like peptide 1 and type 1 diabetes: NOD ready for prime time?
Irene Hadjiyanni, Daniel J Drucker
Endocrine Reviews
|
October 13, 2016
Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance
Gemma Pujadas, Daniel J Drucker
Molecular Endocrinology (Baltimore, Md.)
|
September 28, 2002
Pax-2 activates the proglucagon gene promoter but is not essential for proglucagon gene expression or development of proglucagon-producing cell lineages in the murine pancreas or intestine
Grace Flock, Daniel J Drucker
American Journal of Physiology. Endocrinology and Metabolism
|
January 1, 2009
Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes
Safina Ali, Daniel J Drucker
Annual Review of Medicine
|
January 18, 2006
Therapeutic approaches to preserve islet mass in type 2 diabetes
Laurie L Baggio, Daniel J Drucker
The Journal of Nutrition
|
November 11, 2003
Dual regulation of cell proliferation and survival via activation of glucagon-like peptide-2 receptor signaling
Jennifer L Estall, Daniel J Drucker
Endocrinology
|
November 30, 2019
Proglucagon-Derived Peptides, Glucose-Dependent Insulinotropic Polypeptide, and Dipeptidyl Peptidase-4-Mechanisms of Action in Adipose Tissue
Jacqueline L Beaudry, Daniel J Drucker
Annual Review of Nutrition
|
April 11, 2006
Glucagon-like Peptide-2
Jennifer L Estall, Daniel J Drucker
Page
of 32